Ask AI
ProCE Banner Activity

CT041-ST-01: Randomized Phase II Study of Satri-cel vs Physician’s Choice Treatment for Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Conference Coverage
Slideset

Primary results from the randomized phase II CT041-ST-01 trial in patients with previously treated CLDN18.2-positive advanced gastric or gastroesophageal cancer showed that the CLDN18.2-directed CAR T-cell therapy satricabtagene autoleucel provided a significant PFS benefit and clinically meaningful OS benefit over standard of care with a manageable safety profile.

Released: June 10, 2025

Expiration: December 09, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Daiichi Sankyo, Inc. and Genentech, a member of the Roche Group.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group